%0 Journal Article %1 Shih:2015:Cancer:25585890 %A Shih, H A %A Sherman, J C %A Nachtigall, L B %A Colvin, M K %A Fullerton, B C %A Daartz, J %A Winrich, B K %A Batchelor, T T %A Thornton, L T %A Mancuso, S M %A Saums, M K %A Oh, K S %A Curry, W T %A Loeffler, J S %A Yeap, B Y %D 2015 %J Cancer %K fulltext glioma irradiation low-grade proton therapy who who-grade-2 %N 10 %P 1712-1719 %R 10.1002/cncr.29237 %T Proton therapy for low-grade gliomas: Results from a prospective trial %U https://www.ncbi.nlm.nih.gov/pubmed/25585890 %V 121 %X In this prospective study, the authors evaluated potential treatment toxicity and progression-free survival in patients with low-grade glioma who received treatment with proton radiation therapy.Twenty patients with World Health Organization grade 2 glioma who were eligible for radiation therapy were enrolled in a prospective, single-arm trial of proton therapy. The patients received proton therapy at a dose of 54 Gy (relative biological effectiveness) in 30 fractions. Comprehensive baseline and regular post-treatment evaluations of neurocognitive function, neuroendocrine function, and quality of life (QOL) were performed.All 20 patients (median age, 37.5 years) tolerated treatment without difficulty. The median follow-up after proton therapy was 5.1 years. At baseline, intellectual functioning was within the normal range for the group and remained stable over time. Visuospatial ability, attention/working memory, and executive functioning also were within normal limits; however, baseline neurocognitive impairments were observed in language, memory, and processing speed in 8 patients. There was no overall decline in cognitive functioning over time. New endocrine dysfunction was detected in 6 patients, and all but 1 had received direct irradiation of the hypothalamic-pituitary axis. QOL assessment revealed no changes over time. The progression-free survival rate at 3 years was 85%, but it dropped to 40% at 5 years.Patients with low-grade glioma tolerate proton therapy well, and a subset develops neuroendocrine deficiencies. There is no evidence for overall decline in cognitive function or QOL.

@article{Shih:2015:Cancer:25585890, abstract = {In this prospective study, the authors evaluated potential treatment toxicity and progression-free survival in patients with low-grade glioma who received treatment with proton radiation therapy.Twenty patients with World Health Organization grade 2 glioma who were eligible for radiation therapy were enrolled in a prospective, single-arm trial of proton therapy. The patients received proton therapy at a dose of 54 Gy (relative biological effectiveness) in 30 fractions. Comprehensive baseline and regular post-treatment evaluations of neurocognitive function, neuroendocrine function, and quality of life (QOL) were performed.All 20 patients (median age, 37.5 years) tolerated treatment without difficulty. The median follow-up after proton therapy was 5.1 years. At baseline, intellectual functioning was within the normal range for the group and remained stable over time. Visuospatial ability, attention/working memory, and executive functioning also were within normal limits; however, baseline neurocognitive impairments were observed in language, memory, and processing speed in 8 patients. There was no overall decline in cognitive functioning over time. New endocrine dysfunction was detected in 6 patients, and all but 1 had received direct irradiation of the hypothalamic-pituitary axis. QOL assessment revealed no changes over time. The progression-free survival rate at 3 years was 85%, but it dropped to 40% at 5 years.Patients with low-grade glioma tolerate proton therapy well, and a subset develops neuroendocrine deficiencies. There is no evidence for overall decline in cognitive function or QOL.}, added-at = {2017-02-19T20:02:42.000+0100}, author = {Shih, H A and Sherman, J C and Nachtigall, L B and Colvin, M K and Fullerton, B C and Daartz, J and Winrich, B K and Batchelor, T T and Thornton, L T and Mancuso, S M and Saums, M K and Oh, K S and Curry, W T and Loeffler, J S and Yeap, B Y}, biburl = {https://www.bibsonomy.org/bibtex/2e3928e6a7ce0226e23e5726a61c0abec/marcsaric}, description = {Proton therapy for low-grade gliomas: Results from a prospective trial. - PubMed - NCBI}, doi = {10.1002/cncr.29237}, interhash = {91f4401bd5a5e2ab90fa26a59cb0181e}, intrahash = {e3928e6a7ce0226e23e5726a61c0abec}, journal = {Cancer}, keywords = {fulltext glioma irradiation low-grade proton therapy who who-grade-2}, month = may, number = 10, pages = {1712-1719}, pmid = {25585890}, timestamp = {2017-10-07T22:58:55.000+0200}, title = {Proton therapy for low-grade gliomas: Results from a prospective trial}, url = {https://www.ncbi.nlm.nih.gov/pubmed/25585890}, volume = 121, year = 2015 }